The ILCA School provides fellows in gastroenterology, hepatology, basics/transitional researchers and other liver cancer-related professionals an opportunity to enhance their scientific experience by attending a multidisciplinary programme delivered by the most eminent international liver cancer specialists.
Sign today and join to get the deepest knowledge on:
Understanding the pathogenesis of hepatocellular carcinoma and how to translate this knowledge in clinical practice
Knowing the effect of antiviral treatment on the natural history of HCC
Understanding the place of curative treatments (transplantation, resection and ablation) in management of early HCC
Describing how radiology could help for the diagnosis and the assessment of the radiological response of HCC
Defining the role of pathology in HCC management
Discussing the evidence about SIRT and tyrosine kinase inhibitors in advanced HCC
Friday 11th December 2020
08:25-08:30: Jean-Charles Nault (Avicenne Hospital, Bobigny, APHP, Cordeliers research center, Paris), Eric Vibert (Paul Brousse hospital, Villejuif, APHP)
The Hepatocellular Carcinoma Session Risk factors, screening and diagnosis of HCC: What is new?
08:30-08:45: Perspective on epidemiology and HCC screening in the era of NASH -Nathalie Ganne-Carrie (Avicenne Hospital, Bobigny, APHP, Cordeliers research centre, Paris)
08:45-09:00: Understanding the physiopathology of NASH related HCC – Mathias Heikenwalder (Heidelberg, DKFZ)
09:00-09:15: Update on the Imaging Diagnosis of HCC – Alain Luciani (Mondor Hospital, Créteil, APHP)
09:15-09:30: The future of HCC pathology – Julien Calderaro (Mondor Hospital, Créteil, APHP)
09:30-10:00: Blast session on hot topic: controversies in HCC screening and diagnosis
Impact of antiviral treatment on tumor occurrence and recurrence – Pierre Nahon (Avicenne Hospital, Bobigny, APHP, Cordeliers research centre, Paris
Why and how to assess non-tumor liver in HCC patients ? – François Durand (Beaujon Hospital, Clichy, APHP)
10:00-10:30 Virtual Coffee break
Early HCC: can we go beyond guidelines?
10:30-10:45: Preclinical models of HCC and prediction of therapeutic response – Sandra Rebouissou (Cordeliers research centre, Paris)
10:45-11:00: Why and how to expend criteria for surgery? – Eric Vibert (Paul Brousse Hospital, Villejuif, APHP)
11:00-11:15: Current knowledge and innovation in percutaneous treatment of HCC – Olivier Seror (Avicenne Hospital, Bobigny, APHP, Cordeliers research centre, Paris)
11:15-11:30: Blast session on hot topic: can we improve treatment of early HCC?
The place of mini-invasive surgery: short term advantages and bridge to liver transplantation – Olivier Scatton (Pitié-Salpétrière Hospital, Paris, APHP)
Can we expend criteria of liver transplantation beyond composite criteria ? – Christophe Duvoux (Mondor Hospital, Créteil, APHP)